nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP1A2—Erlotinib—lung cancer	0.0437	0.117	CbGbCtD
Imiquimod—CYP3A4—Topotecan—lung cancer	0.0423	0.113	CbGbCtD
Imiquimod—CYP3A4—Gefitinib—lung cancer	0.0387	0.104	CbGbCtD
Imiquimod—CYP3A4—Teniposide—lung cancer	0.0375	0.101	CbGbCtD
Imiquimod—CYP1A2—Etoposide—lung cancer	0.0316	0.0846	CbGbCtD
Imiquimod—CYP3A4—Vinorelbine—lung cancer	0.0298	0.0799	CbGbCtD
Imiquimod—CYP3A4—Crizotinib—lung cancer	0.0237	0.0636	CbGbCtD
Imiquimod—CYP3A4—Erlotinib—lung cancer	0.0229	0.0613	CbGbCtD
Imiquimod—CYP3A4—Paclitaxel—lung cancer	0.0209	0.0561	CbGbCtD
Imiquimod—CYP3A4—Irinotecan—lung cancer	0.0207	0.0554	CbGbCtD
Imiquimod—CYP3A4—Vinblastine—lung cancer	0.0184	0.0492	CbGbCtD
Imiquimod—CYP3A4—Etoposide—lung cancer	0.0166	0.0443	CbGbCtD
Imiquimod—TLR8—respiratory system—lung cancer	0.0155	0.311	CbGeAlD
Imiquimod—CYP3A4—Docetaxel—lung cancer	0.0151	0.0406	CbGbCtD
Imiquimod—CYP3A4—Doxorubicin—lung cancer	0.0113	0.0302	CbGbCtD
Imiquimod—TLR8—bone marrow—lung cancer	0.00907	0.182	CbGeAlD
Imiquimod—TLR8—lung—lung cancer	0.00822	0.165	CbGeAlD
Imiquimod—TLR8—lymph node—lung cancer	0.00562	0.113	CbGeAlD
Imiquimod—TLR7—lung—lung cancer	0.00518	0.104	CbGeAlD
Imiquimod—TLR7—lymph node—lung cancer	0.00355	0.0712	CbGeAlD
Imiquimod—CYP1A2—respiratory system—lung cancer	0.00176	0.0353	CbGeAlD
Imiquimod—CYP1A2—lung—lung cancer	0.000934	0.0187	CbGeAlD
Imiquimod—Cough—Docetaxel—lung cancer	0.000137	0.000367	CcSEcCtD
Imiquimod—Hepatobiliary disease—Methotrexate—lung cancer	0.000137	0.000367	CcSEcCtD
Imiquimod—Insomnia—Paclitaxel—lung cancer	0.000136	0.000366	CcSEcCtD
Imiquimod—Hypersensitivity—Irinotecan—lung cancer	0.000136	0.000366	CcSEcCtD
Imiquimod—Convulsion—Docetaxel—lung cancer	0.000136	0.000364	CcSEcCtD
Imiquimod—Paraesthesia—Paclitaxel—lung cancer	0.000135	0.000364	CcSEcCtD
Imiquimod—Hypertension—Docetaxel—lung cancer	0.000135	0.000363	CcSEcCtD
Imiquimod—Bronchitis—Doxorubicin—lung cancer	0.000135	0.000362	CcSEcCtD
Imiquimod—Dyspnoea—Paclitaxel—lung cancer	0.000134	0.000361	CcSEcCtD
Imiquimod—Somnolence—Paclitaxel—lung cancer	0.000134	0.00036	CcSEcCtD
Imiquimod—Decreased appetite—Etoposide—lung cancer	0.000134	0.000359	CcSEcCtD
Imiquimod—Chest pain—Docetaxel—lung cancer	0.000133	0.000358	CcSEcCtD
Imiquimod—Arthralgia—Docetaxel—lung cancer	0.000133	0.000358	CcSEcCtD
Imiquimod—Myalgia—Docetaxel—lung cancer	0.000133	0.000358	CcSEcCtD
Imiquimod—Pancytopenia—Doxorubicin—lung cancer	0.000133	0.000358	CcSEcCtD
Imiquimod—Nausea—Vinorelbine—lung cancer	0.000133	0.000358	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Etoposide—lung cancer	0.000133	0.000357	CcSEcCtD
Imiquimod—Dyspepsia—Paclitaxel—lung cancer	0.000133	0.000356	CcSEcCtD
Imiquimod—Body temperature increased—Cisplatin—lung cancer	0.000133	0.000356	CcSEcCtD
Imiquimod—Asthenia—Irinotecan—lung cancer	0.000133	0.000356	CcSEcCtD
Imiquimod—Fatigue—Etoposide—lung cancer	0.000133	0.000356	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000132	0.000356	CcSEcCtD
Imiquimod—Pain—Etoposide—lung cancer	0.000131	0.000353	CcSEcCtD
Imiquimod—Dysuria—Doxorubicin—lung cancer	0.000131	0.000352	CcSEcCtD
Imiquimod—Decreased appetite—Paclitaxel—lung cancer	0.000131	0.000352	CcSEcCtD
Imiquimod—Dry mouth—Docetaxel—lung cancer	0.00013	0.00035	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Doxorubicin—lung cancer	0.00013	0.00035	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—lung cancer	0.00013	0.00035	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00013	0.00035	CcSEcCtD
Imiquimod—Fatigue—Paclitaxel—lung cancer	0.00013	0.000349	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—lung cancer	0.00013	0.000348	CcSEcCtD
Imiquimod—Asthenia—Gemcitabine—lung cancer	0.000129	0.000347	CcSEcCtD
Imiquimod—Pain—Paclitaxel—lung cancer	0.000129	0.000346	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—lung cancer	0.000129	0.000346	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—lung cancer	0.000128	0.000344	CcSEcCtD
Imiquimod—Photosensitivity reaction—Doxorubicin—lung cancer	0.000128	0.000344	CcSEcCtD
Imiquimod—Oedema—Docetaxel—lung cancer	0.000128	0.000343	CcSEcCtD
Imiquimod—Pruritus—Gemcitabine—lung cancer	0.000127	0.000342	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—lung cancer	0.000127	0.000341	CcSEcCtD
Imiquimod—Infection—Docetaxel—lung cancer	0.000127	0.000341	CcSEcCtD
Imiquimod—Feeling abnormal—Etoposide—lung cancer	0.000127	0.00034	CcSEcCtD
Imiquimod—Diarrhoea—Irinotecan—lung cancer	0.000126	0.00034	CcSEcCtD
Imiquimod—Gastrointestinal pain—Etoposide—lung cancer	0.000126	0.000338	CcSEcCtD
Imiquimod—Shock—Docetaxel—lung cancer	0.000126	0.000338	CcSEcCtD
Imiquimod—Nervous system disorder—Docetaxel—lung cancer	0.000125	0.000337	CcSEcCtD
Imiquimod—Infestation NOS—Doxorubicin—lung cancer	0.000125	0.000336	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—lung cancer	0.000125	0.000336	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—lung cancer	0.000125	0.000336	CcSEcCtD
Imiquimod—Tachycardia—Docetaxel—lung cancer	0.000125	0.000335	CcSEcCtD
Imiquimod—Feeling abnormal—Paclitaxel—lung cancer	0.000124	0.000334	CcSEcCtD
Imiquimod—Skin disorder—Docetaxel—lung cancer	0.000124	0.000333	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000124	0.000333	CcSEcCtD
Imiquimod—Hypersensitivity—Cisplatin—lung cancer	0.000124	0.000332	CcSEcCtD
Imiquimod—Gastrointestinal pain—Paclitaxel—lung cancer	0.000123	0.000331	CcSEcCtD
Imiquimod—Diarrhoea—Gemcitabine—lung cancer	0.000123	0.000331	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—lung cancer	0.000123	0.000329	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—lung cancer	0.000123	0.000329	CcSEcCtD
Imiquimod—Dizziness—Irinotecan—lung cancer	0.000122	0.000328	CcSEcCtD
Imiquimod—Urticaria—Etoposide—lung cancer	0.000122	0.000328	CcSEcCtD
Imiquimod—Anorexia—Docetaxel—lung cancer	0.000122	0.000327	CcSEcCtD
Imiquimod—Body temperature increased—Etoposide—lung cancer	0.000122	0.000327	CcSEcCtD
Imiquimod—Abdominal pain—Etoposide—lung cancer	0.000122	0.000327	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—lung cancer	0.000122	0.000326	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—lung cancer	0.000122	0.000326	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—lung cancer	0.000121	0.000325	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—lung cancer	0.000121	0.000325	CcSEcCtD
Imiquimod—Asthenia—Cisplatin—lung cancer	0.00012	0.000323	CcSEcCtD
Imiquimod—Urticaria—Paclitaxel—lung cancer	0.00012	0.000322	CcSEcCtD
Imiquimod—Abdominal pain—Paclitaxel—lung cancer	0.000119	0.00032	CcSEcCtD
Imiquimod—Body temperature increased—Paclitaxel—lung cancer	0.000119	0.00032	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—lung cancer	0.000118	0.000318	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—lung cancer	0.000118	0.000316	CcSEcCtD
Imiquimod—Vomiting—Irinotecan—lung cancer	0.000117	0.000316	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—lung cancer	0.000117	0.000315	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—lung cancer	0.000117	0.000315	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—lung cancer	0.000117	0.000314	CcSEcCtD
Imiquimod—Rash—Irinotecan—lung cancer	0.000117	0.000313	CcSEcCtD
Imiquimod—Dermatitis—Irinotecan—lung cancer	0.000116	0.000313	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000116	0.000313	CcSEcCtD
Imiquimod—Chills—Methotrexate—lung cancer	0.000116	0.000312	CcSEcCtD
Imiquimod—Headache—Irinotecan—lung cancer	0.000116	0.000311	CcSEcCtD
Imiquimod—Insomnia—Docetaxel—lung cancer	0.000116	0.00031	CcSEcCtD
Imiquimod—Diarrhoea—Cisplatin—lung cancer	0.000115	0.000308	CcSEcCtD
Imiquimod—Paraesthesia—Docetaxel—lung cancer	0.000115	0.000308	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—lung cancer	0.000115	0.000308	CcSEcCtD
Imiquimod—Vomiting—Gemcitabine—lung cancer	0.000114	0.000308	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—SRC—lung cancer	0.000114	0.000557	CbGpPWpGaD
Imiquimod—Dyspnoea—Docetaxel—lung cancer	0.000114	0.000306	CcSEcCtD
Imiquimod—Somnolence—Docetaxel—lung cancer	0.000114	0.000305	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—lung cancer	0.000114	0.000305	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTM1—lung cancer	0.000114	0.000554	CbGpPWpGaD
Imiquimod—Rash—Gemcitabine—lung cancer	0.000114	0.000305	CcSEcCtD
Imiquimod—Dermatitis—Gemcitabine—lung cancer	0.000113	0.000305	CcSEcCtD
Imiquimod—Hypersensitivity—Etoposide—lung cancer	0.000113	0.000304	CcSEcCtD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000113	0.000551	CbGpPWpGaD
Imiquimod—Malnutrition—Methotrexate—lung cancer	0.000113	0.000303	CcSEcCtD
Imiquimod—Erythema—Methotrexate—lung cancer	0.000113	0.000303	CcSEcCtD
Imiquimod—Haemoglobin—Doxorubicin—lung cancer	0.000113	0.000303	CcSEcCtD
Imiquimod—Headache—Gemcitabine—lung cancer	0.000113	0.000303	CcSEcCtD
Imiquimod—TLR8—Immune System—MDM2—lung cancer	0.000113	0.000549	CbGpPWpGaD
Imiquimod—Rhinitis—Doxorubicin—lung cancer	0.000113	0.000302	CcSEcCtD
Imiquimod—Dyspepsia—Docetaxel—lung cancer	0.000112	0.000302	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—lung cancer	0.000112	0.000302	CcSEcCtD
Imiquimod—TLR8—Immune System—RAF1—lung cancer	0.000112	0.000548	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTA4—lung cancer	0.000112	0.000545	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—MDM2—lung cancer	0.000112	0.000545	CbGpPWpGaD
Imiquimod—Pharyngitis—Doxorubicin—lung cancer	0.000111	0.000299	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000111	0.000544	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—lung cancer	0.000111	0.000543	CbGpPWpGaD
Imiquimod—Decreased appetite—Docetaxel—lung cancer	0.000111	0.000298	CcSEcCtD
Imiquimod—Hypersensitivity—Paclitaxel—lung cancer	0.000111	0.000298	CcSEcCtD
Imiquimod—TLR8—Immune System—ERBB2—lung cancer	0.000111	0.000542	CbGpPWpGaD
Imiquimod—Urinary tract disorder—Doxorubicin—lung cancer	0.000111	0.000298	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Docetaxel—lung cancer	0.00011	0.000296	CcSEcCtD
Imiquimod—Asthenia—Etoposide—lung cancer	0.00011	0.000296	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—lung cancer	0.00011	0.000296	CcSEcCtD
Imiquimod—Fatigue—Docetaxel—lung cancer	0.00011	0.000296	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	0.00011	0.000538	CbGpPWpGaD
Imiquimod—Urethral disorder—Doxorubicin—lung cancer	0.00011	0.000296	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—NRAS—lung cancer	0.00011	0.000536	CbGpPWpGaD
Imiquimod—Nausea—Irinotecan—lung cancer	0.00011	0.000295	CcSEcCtD
Imiquimod—TLR8—Immune System—MTOR—lung cancer	0.000109	0.000535	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CB—lung cancer	0.000109	0.000535	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD4—lung cancer	0.000109	0.000534	CbGpPWpGaD
Imiquimod—Pain—Docetaxel—lung cancer	0.000109	0.000294	CcSEcCtD
Imiquimod—Back pain—Methotrexate—lung cancer	0.000109	0.000293	CcSEcCtD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000109	0.000532	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTA2—lung cancer	0.000109	0.000531	CbGpPWpGaD
Imiquimod—Pruritus—Etoposide—lung cancer	0.000109	0.000292	CcSEcCtD
Imiquimod—TLR7—Immune System—KIT—lung cancer	0.000108	0.000529	CbGpPWpGaD
Imiquimod—Visual impairment—Doxorubicin—lung cancer	0.000108	0.000291	CcSEcCtD
Imiquimod—Asthenia—Paclitaxel—lung cancer	0.000108	0.000291	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—lung cancer	0.000108	0.000525	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—HPGDS—lung cancer	0.000108	0.000525	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGF—lung cancer	0.000107	0.000523	CbGpPWpGaD
Imiquimod—Nausea—Gemcitabine—lung cancer	0.000107	0.000287	CcSEcCtD
Imiquimod—Vomiting—Cisplatin—lung cancer	0.000107	0.000287	CcSEcCtD
Imiquimod—Pruritus—Paclitaxel—lung cancer	0.000107	0.000287	CcSEcCtD
Imiquimod—Erythema multiforme—Doxorubicin—lung cancer	0.000106	0.000285	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—HRAS—lung cancer	0.000106	0.000518	CbGpPWpGaD
Imiquimod—Rash—Cisplatin—lung cancer	0.000106	0.000284	CcSEcCtD
Imiquimod—Dermatitis—Cisplatin—lung cancer	0.000106	0.000284	CcSEcCtD
Imiquimod—Feeling abnormal—Docetaxel—lung cancer	0.000105	0.000283	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—MAPK3—lung cancer	0.000105	0.000514	CbGpPWpGaD
Imiquimod—Diarrhoea—Etoposide—lung cancer	0.000105	0.000283	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTA1—lung cancer	0.000105	0.000513	CbGpPWpGaD
Imiquimod—Eye disorder—Doxorubicin—lung cancer	0.000105	0.000282	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—lung cancer	0.000105	0.000281	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—lung cancer	0.000105	0.000281	CcSEcCtD
Imiquimod—Gastrointestinal pain—Docetaxel—lung cancer	0.000104	0.000281	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTT1—lung cancer	0.000104	0.000509	CbGpPWpGaD
Imiquimod—Flushing—Doxorubicin—lung cancer	0.000104	0.00028	CcSEcCtD
Imiquimod—Diarrhoea—Paclitaxel—lung cancer	0.000103	0.000277	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—CYP2A6—lung cancer	0.000103	0.000503	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GCLC—lung cancer	0.000103	0.000503	CbGpPWpGaD
Imiquimod—Angiopathy—Doxorubicin—lung cancer	0.000102	0.000274	CcSEcCtD
Imiquimod—Malaise—Methotrexate—lung cancer	0.000102	0.000273	CcSEcCtD
Imiquimod—Dizziness—Etoposide—lung cancer	0.000102	0.000273	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—IL6—lung cancer	0.000101	0.000495	CbGpPWpGaD
Imiquimod—Immune system disorder—Doxorubicin—lung cancer	0.000101	0.000272	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—lung cancer	0.000101	0.000272	CcSEcCtD
Imiquimod—Body temperature increased—Docetaxel—lung cancer	0.000101	0.000271	CcSEcCtD
Imiquimod—Abdominal pain—Docetaxel—lung cancer	0.000101	0.000271	CcSEcCtD
Imiquimod—TLR7—Immune System—CASP8—lung cancer	0.000101	0.000492	CbGpPWpGaD
Imiquimod—Chills—Doxorubicin—lung cancer	0.000101	0.000271	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—lung cancer	0.000101	0.000491	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL6R—lung cancer	0.000101	0.000491	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL2—lung cancer	0.000101	0.000491	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CREBBP—lung cancer	0.0001	0.00049	CbGpPWpGaD
Imiquimod—Arrhythmia—Doxorubicin—lung cancer	0.0001	0.000269	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—EGFR—lung cancer	0.0001	0.000489	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	9.97e-05	0.000487	CbGpPWpGaD
Imiquimod—Dizziness—Paclitaxel—lung cancer	9.97e-05	0.000268	CcSEcCtD
Imiquimod—Nausea—Cisplatin—lung cancer	9.97e-05	0.000268	CcSEcCtD
Imiquimod—TLR7—Immune System—CDH1—lung cancer	9.97e-05	0.000487	CbGpPWpGaD
Imiquimod—Alopecia—Doxorubicin—lung cancer	9.92e-05	0.000266	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	9.91e-05	0.000484	CbGpPWpGaD
Imiquimod—Cough—Methotrexate—lung cancer	9.84e-05	0.000265	CcSEcCtD
Imiquimod—Mental disorder—Doxorubicin—lung cancer	9.83e-05	0.000264	CcSEcCtD
Imiquimod—TLR8—Immune System—JUN—lung cancer	9.78e-05	0.000478	CbGpPWpGaD
Imiquimod—Convulsion—Methotrexate—lung cancer	9.77e-05	0.000263	CcSEcCtD
Imiquimod—Vomiting—Etoposide—lung cancer	9.77e-05	0.000263	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—lung cancer	9.77e-05	0.000262	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—lung cancer	9.77e-05	0.000262	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—UGT1A1—lung cancer	9.76e-05	0.000477	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	9.7e-05	0.000474	CbGpPWpGaD
Imiquimod—Rash—Etoposide—lung cancer	9.69e-05	0.00026	CcSEcCtD
Imiquimod—Dermatitis—Etoposide—lung cancer	9.68e-05	0.00026	CcSEcCtD
Imiquimod—Headache—Etoposide—lung cancer	9.63e-05	0.000259	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	9.62e-05	0.00047	CbGpPWpGaD
Imiquimod—Arthralgia—Methotrexate—lung cancer	9.6e-05	0.000258	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—lung cancer	9.6e-05	0.000258	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—lung cancer	9.6e-05	0.000258	CcSEcCtD
Imiquimod—Vomiting—Paclitaxel—lung cancer	9.58e-05	0.000257	CcSEcCtD
Imiquimod—TLR7—Immune System—MAP2K1—lung cancer	9.58e-05	0.000468	CbGpPWpGaD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	9.54e-05	0.000256	CcSEcCtD
Imiquimod—TLR7—Immune System—PIK3CD—lung cancer	9.52e-05	0.000465	CbGpPWpGaD
Imiquimod—Rash—Paclitaxel—lung cancer	9.5e-05	0.000255	CcSEcCtD
Imiquimod—Dermatitis—Paclitaxel—lung cancer	9.49e-05	0.000255	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—lung cancer	9.49e-05	0.000255	CcSEcCtD
Imiquimod—TLR8—Immune System—CDKN1A—lung cancer	9.48e-05	0.000463	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PTEN—lung cancer	9.46e-05	0.000462	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KRAS—lung cancer	9.45e-05	0.000462	CbGpPWpGaD
Imiquimod—Back pain—Doxorubicin—lung cancer	9.45e-05	0.000254	CcSEcCtD
Imiquimod—Headache—Paclitaxel—lung cancer	9.44e-05	0.000254	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	9.42e-05	0.00046	CbGpPWpGaD
Imiquimod—Hypersensitivity—Docetaxel—lung cancer	9.41e-05	0.000253	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—lung cancer	9.4e-05	0.000459	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—AKT1—lung cancer	9.36e-05	0.000457	CbGpPWpGaD
Imiquimod—Asthenia—Docetaxel—lung cancer	9.17e-05	0.000246	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	9.15e-05	0.000447	CbGpPWpGaD
Imiquimod—Infection—Methotrexate—lung cancer	9.15e-05	0.000246	CcSEcCtD
Imiquimod—Nausea—Etoposide—lung cancer	9.13e-05	0.000245	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—lung cancer	9.06e-05	0.000244	CcSEcCtD
Imiquimod—Pruritus—Docetaxel—lung cancer	9.04e-05	0.000243	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—lung cancer	9.03e-05	0.000243	CcSEcCtD
Imiquimod—TLR8—Immune System—EP300—lung cancer	9.02e-05	0.000441	CbGpPWpGaD
Imiquimod—Agitation—Doxorubicin—lung cancer	8.98e-05	0.000241	CcSEcCtD
Imiquimod—Nausea—Paclitaxel—lung cancer	8.95e-05	0.000241	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EP300—lung cancer	8.94e-05	0.000437	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	8.94e-05	0.000437	CbGpPWpGaD
Imiquimod—Skin disorder—Methotrexate—lung cancer	8.94e-05	0.00024	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—lung cancer	8.9e-05	0.000239	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—POMC—lung cancer	8.84e-05	0.000432	CbGpPWpGaD
Imiquimod—Malaise—Doxorubicin—lung cancer	8.81e-05	0.000237	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—lung cancer	8.78e-05	0.000236	CcSEcCtD
Imiquimod—TLR8—Immune System—SRC—lung cancer	8.77e-05	0.000428	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP2E1—lung cancer	8.76e-05	0.000428	CbGpPWpGaD
Imiquimod—Syncope—Doxorubicin—lung cancer	8.76e-05	0.000235	CcSEcCtD
Imiquimod—Diarrhoea—Docetaxel—lung cancer	8.74e-05	0.000235	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	8.7e-05	0.000425	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—SRC—lung cancer	8.7e-05	0.000425	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CA—lung cancer	8.68e-05	0.000424	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP2E1—lung cancer	8.64e-05	0.000422	CbGpPWpGaD
Imiquimod—Palpitations—Doxorubicin—lung cancer	8.63e-05	0.000232	CcSEcCtD
Imiquimod—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	8.61e-05	0.00042	CbGpPWpGaD
Imiquimod—Loss of consciousness—Doxorubicin—lung cancer	8.59e-05	0.000231	CcSEcCtD
Imiquimod—TLR7—Immune System—MDM2—lung cancer	8.53e-05	0.000416	CbGpPWpGaD
Imiquimod—Cough—Doxorubicin—lung cancer	8.52e-05	0.000229	CcSEcCtD
Imiquimod—TLR7—Immune System—RAF1—lung cancer	8.5e-05	0.000415	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—lung cancer	8.47e-05	0.000414	CbGpPWpGaD
Imiquimod—Convulsion—Doxorubicin—lung cancer	8.46e-05	0.000227	CcSEcCtD
Imiquimod—TLR8—Immune System—STAT3—lung cancer	8.46e-05	0.000413	CbGpPWpGaD
Imiquimod—Dizziness—Docetaxel—lung cancer	8.45e-05	0.000227	CcSEcCtD
Imiquimod—TLR8—Immune System—NRAS—lung cancer	8.44e-05	0.000412	CbGpPWpGaD
Imiquimod—Hypertension—Doxorubicin—lung cancer	8.43e-05	0.000227	CcSEcCtD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	8.41e-05	0.000411	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERBB2—lung cancer	8.41e-05	0.000411	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Methotrexate—lung cancer	8.39e-05	0.000225	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—lung cancer	8.37e-05	0.000409	CbGpPWpGaD
Imiquimod—Insomnia—Methotrexate—lung cancer	8.33e-05	0.000224	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—lung cancer	8.32e-05	0.000223	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—lung cancer	8.32e-05	0.000223	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—lung cancer	8.32e-05	0.000223	CcSEcCtD
Imiquimod—TLR7—Immune System—MTOR—lung cancer	8.3e-05	0.000405	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CB—lung cancer	8.3e-05	0.000405	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—HPGDS—lung cancer	8.3e-05	0.000405	CbGpPWpGaD
Imiquimod—Anxiety—Doxorubicin—lung cancer	8.29e-05	0.000223	CcSEcCtD
Imiquimod—TLR7—Immune System—CD4—lung cancer	8.28e-05	0.000404	CbGpPWpGaD
Imiquimod—Paraesthesia—Methotrexate—lung cancer	8.27e-05	0.000222	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.26e-05	0.000222	CcSEcCtD
Imiquimod—Discomfort—Doxorubicin—lung cancer	8.22e-05	0.000221	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—lung cancer	8.21e-05	0.000221	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—lung cancer	8.19e-05	0.00022	CcSEcCtD
Imiquimod—Dry mouth—Doxorubicin—lung cancer	8.13e-05	0.000219	CcSEcCtD
Imiquimod—Vomiting—Docetaxel—lung cancer	8.12e-05	0.000218	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—lung cancer	8.1e-05	0.000218	CcSEcCtD
Imiquimod—TLR8—Immune System—MAPK3—lung cancer	8.08e-05	0.000395	CbGpPWpGaD
Imiquimod—Rash—Docetaxel—lung cancer	8.05e-05	0.000216	CcSEcCtD
Imiquimod—Dermatitis—Docetaxel—lung cancer	8.05e-05	0.000216	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTT1—lung cancer	8.05e-05	0.000393	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HRAS—lung cancer	8.03e-05	0.000392	CbGpPWpGaD
Imiquimod—Decreased appetite—Methotrexate—lung cancer	8e-05	0.000215	CcSEcCtD
Imiquimod—Headache—Docetaxel—lung cancer	8e-05	0.000215	CcSEcCtD
Imiquimod—Oedema—Doxorubicin—lung cancer	7.97e-05	0.000214	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—CYP2A6—lung cancer	7.95e-05	0.000388	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GCLC—lung cancer	7.95e-05	0.000388	CbGpPWpGaD
Imiquimod—Gastrointestinal disorder—Methotrexate—lung cancer	7.95e-05	0.000214	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—lung cancer	7.94e-05	0.000213	CcSEcCtD
Imiquimod—Infection—Doxorubicin—lung cancer	7.92e-05	0.000213	CcSEcCtD
Imiquimod—Pain—Methotrexate—lung cancer	7.87e-05	0.000212	CcSEcCtD
Imiquimod—Shock—Doxorubicin—lung cancer	7.84e-05	0.000211	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—lung cancer	7.82e-05	0.00021	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—lung cancer	7.79e-05	0.000381	CbGpPWpGaD
Imiquimod—Tachycardia—Doxorubicin—lung cancer	7.78e-05	0.000209	CcSEcCtD
Imiquimod—Skin disorder—Doxorubicin—lung cancer	7.74e-05	0.000208	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—lung cancer	7.71e-05	0.000207	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—IL6—lung cancer	7.69e-05	0.000376	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGFR—lung cancer	7.69e-05	0.000376	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—lung cancer	7.62e-05	0.000372	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	7.62e-05	0.000372	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL2—lung cancer	7.62e-05	0.000372	CbGpPWpGaD
Imiquimod—Anorexia—Doxorubicin—lung cancer	7.6e-05	0.000204	CcSEcCtD
Imiquimod—Nausea—Docetaxel—lung cancer	7.59e-05	0.000204	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—lung cancer	7.59e-05	0.000204	CcSEcCtD
Imiquimod—Gastrointestinal pain—Methotrexate—lung cancer	7.53e-05	0.000202	CcSEcCtD
Imiquimod—TLR7—Immune System—JUN—lung cancer	7.41e-05	0.000362	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	7.33e-05	0.000358	CbGpPWpGaD
Imiquimod—Urticaria—Methotrexate—lung cancer	7.31e-05	0.000197	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—lung cancer	7.28e-05	0.000196	CcSEcCtD
Imiquimod—Abdominal pain—Methotrexate—lung cancer	7.28e-05	0.000196	CcSEcCtD
Imiquimod—TLR8—Immune System—KRAS—lung cancer	7.26e-05	0.000355	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.26e-05	0.000195	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTP1—lung cancer	7.23e-05	0.000353	CbGpPWpGaD
Imiquimod—Insomnia—Doxorubicin—lung cancer	7.21e-05	0.000194	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—lung cancer	7.2e-05	0.000352	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1A—lung cancer	7.19e-05	0.000351	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PTEN—lung cancer	7.17e-05	0.00035	CbGpPWpGaD
Imiquimod—Paraesthesia—Doxorubicin—lung cancer	7.16e-05	0.000192	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTP1—lung cancer	7.13e-05	0.000348	CbGpPWpGaD
Imiquimod—Dyspnoea—Doxorubicin—lung cancer	7.11e-05	0.000191	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—AKT1—lung cancer	7.09e-05	0.000346	CbGpPWpGaD
Imiquimod—Somnolence—Doxorubicin—lung cancer	7.09e-05	0.00019	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—lung cancer	7.02e-05	0.000189	CcSEcCtD
Imiquimod—Decreased appetite—Doxorubicin—lung cancer	6.93e-05	0.000186	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Doxorubicin—lung cancer	6.88e-05	0.000185	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—lung cancer	6.87e-05	0.000185	CcSEcCtD
Imiquimod—TLR7—Immune System—EP300—lung cancer	6.84e-05	0.000334	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	6.82e-05	0.000333	CbGpPWpGaD
Imiquimod—Pain—Doxorubicin—lung cancer	6.82e-05	0.000183	CcSEcCtD
Imiquimod—Hypersensitivity—Methotrexate—lung cancer	6.78e-05	0.000182	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—CYP2E1—lung cancer	6.76e-05	0.00033	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CA—lung cancer	6.67e-05	0.000326	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	6.67e-05	0.000326	CbGpPWpGaD
Imiquimod—TLR7—Immune System—SRC—lung cancer	6.65e-05	0.000325	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTM1—lung cancer	6.64e-05	0.000324	CbGpPWpGaD
Imiquimod—Asthenia—Methotrexate—lung cancer	6.61e-05	0.000178	CcSEcCtD
Imiquimod—Feeling abnormal—Doxorubicin—lung cancer	6.57e-05	0.000177	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTM1—lung cancer	6.55e-05	0.00032	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Doxorubicin—lung cancer	6.52e-05	0.000175	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—lung cancer	6.51e-05	0.000175	CcSEcCtD
Imiquimod—TLR7—Immune System—STAT3—lung cancer	6.41e-05	0.000313	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NRAS—lung cancer	6.4e-05	0.000312	CbGpPWpGaD
Imiquimod—Urticaria—Doxorubicin—lung cancer	6.33e-05	0.00017	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—lung cancer	6.3e-05	0.000169	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—lung cancer	6.3e-05	0.000169	CcSEcCtD
Imiquimod—Diarrhoea—Methotrexate—lung cancer	6.3e-05	0.000169	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—CYP1A1—lung cancer	6.3e-05	0.000307	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP1A1—lung cancer	6.21e-05	0.000303	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HRAS—lung cancer	6.17e-05	0.000302	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK3—lung cancer	6.13e-05	0.000299	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—lung cancer	6.12e-05	0.000299	CbGpPWpGaD
Imiquimod—Dizziness—Methotrexate—lung cancer	6.09e-05	0.000164	CcSEcCtD
Imiquimod—TLR8—Immune System—IL6—lung cancer	5.91e-05	0.000289	CbGpPWpGaD
Imiquimod—Hypersensitivity—Doxorubicin—lung cancer	5.87e-05	0.000158	CcSEcCtD
Imiquimod—Vomiting—Methotrexate—lung cancer	5.85e-05	0.000157	CcSEcCtD
Imiquimod—TLR7—Immune System—EGFR—lung cancer	5.83e-05	0.000285	CbGpPWpGaD
Imiquimod—Rash—Methotrexate—lung cancer	5.81e-05	0.000156	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—lung cancer	5.8e-05	0.000156	CcSEcCtD
Imiquimod—Headache—Methotrexate—lung cancer	5.77e-05	0.000155	CcSEcCtD
Imiquimod—Asthenia—Doxorubicin—lung cancer	5.72e-05	0.000154	CcSEcCtD
Imiquimod—Pruritus—Doxorubicin—lung cancer	5.64e-05	0.000152	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTP1—lung cancer	5.58e-05	0.000272	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—COL4A3BP—lung cancer	5.54e-05	0.00027	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AZIN2—lung cancer	5.54e-05	0.00027	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KRAS—lung cancer	5.51e-05	0.000269	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	5.5e-05	0.000269	CbGpPWpGaD
Imiquimod—Nausea—Methotrexate—lung cancer	5.47e-05	0.000147	CcSEcCtD
Imiquimod—Diarrhoea—Doxorubicin—lung cancer	5.45e-05	0.000147	CcSEcCtD
Imiquimod—TLR8—Immune System—AKT1—lung cancer	5.45e-05	0.000266	CbGpPWpGaD
Imiquimod—Dizziness—Doxorubicin—lung cancer	5.27e-05	0.000142	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	5.16e-05	0.000252	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTM1—lung cancer	5.13e-05	0.00025	CbGpPWpGaD
Imiquimod—Vomiting—Doxorubicin—lung cancer	5.07e-05	0.000136	CcSEcCtD
Imiquimod—TLR7—Immune System—PIK3CA—lung cancer	5.06e-05	0.000247	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	5.06e-05	0.000247	CbGpPWpGaD
Imiquimod—Rash—Doxorubicin—lung cancer	5.03e-05	0.000135	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—lung cancer	5.02e-05	0.000135	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	5e-05	0.000244	CbGpPWpGaD
Imiquimod—Headache—Doxorubicin—lung cancer	4.99e-05	0.000134	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—CYP1A1—lung cancer	4.86e-05	0.000237	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	4.79e-05	0.000234	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—lung cancer	4.74e-05	0.000127	CcSEcCtD
Imiquimod—CYP1A2—Metabolism—ATP5H—lung cancer	4.71e-05	0.00023	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—POMC—lung cancer	4.69e-05	0.000229	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HRAS—lung cancer	4.68e-05	0.000229	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL6—lung cancer	4.48e-05	0.000219	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	4.33e-05	0.000211	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—COL4A3BP—lung cancer	4.27e-05	0.000209	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AZIN2—lung cancer	4.27e-05	0.000209	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PLBD1—lung cancer	4.2e-05	0.000205	CbGpPWpGaD
Imiquimod—TLR7—Immune System—AKT1—lung cancer	4.13e-05	0.000202	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	4.13e-05	0.000202	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HSD17B10—lung cancer	3.84e-05	0.000187	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ATP5H—lung cancer	3.63e-05	0.000177	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—POMC—lung cancer	3.62e-05	0.000177	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CKB—lung cancer	3.57e-05	0.000174	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTM2—lung cancer	3.36e-05	0.000164	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CNDP2—lung cancer	3.36e-05	0.000164	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—MTMR3—lung cancer	3.26e-05	0.000159	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PLBD1—lung cancer	3.24e-05	0.000158	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PGAM1—lung cancer	3.18e-05	0.000155	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP2A7—lung cancer	3.03e-05	0.000148	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SDC4—lung cancer	2.97e-05	0.000145	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HSD17B10—lung cancer	2.96e-05	0.000145	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CKB—lung cancer	2.75e-05	0.000135	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—RRM1—lung cancer	2.7e-05	0.000132	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA3—lung cancer	2.7e-05	0.000132	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTM2—lung cancer	2.59e-05	0.000126	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CNDP2—lung cancer	2.59e-05	0.000126	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—B4GALT5—lung cancer	2.54e-05	0.000124	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—MTMR3—lung cancer	2.52e-05	0.000123	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA4—lung cancer	2.47e-05	0.000121	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PGAM1—lung cancer	2.45e-05	0.00012	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	2.42e-05	0.000118	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA2—lung cancer	2.41e-05	0.000118	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP2A7—lung cancer	2.34e-05	0.000114	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA1—lung cancer	2.33e-05	0.000114	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCC3—lung cancer	2.3e-05	0.000112	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SDC4—lung cancer	2.29e-05	0.000112	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AKR1C1—lung cancer	2.23e-05	0.000109	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—UGT1A1—lung cancer	2.16e-05	0.000106	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—RRM1—lung cancer	2.09e-05	0.000102	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA3—lung cancer	2.09e-05	0.000102	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNG11—lung cancer	2.08e-05	0.000102	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.07e-05	0.000101	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALDOA—lung cancer	1.99e-05	9.69e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—B4GALT5—lung cancer	1.96e-05	9.58e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NCOA3—lung cancer	1.93e-05	9.41e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA4—lung cancer	1.91e-05	9.32e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.89e-05	9.25e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCG2—lung cancer	1.87e-05	9.15e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ADCY1—lung cancer	1.87e-05	9.15e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA2—lung cancer	1.86e-05	9.09e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HPGDS—lung cancer	1.84e-05	8.98e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO2—lung cancer	1.84e-05	8.98e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPP2R1B—lung cancer	1.83e-05	8.92e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.8e-05	8.8e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA1—lung cancer	1.79e-05	8.77e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTT1—lung cancer	1.78e-05	8.71e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCC3—lung cancer	1.77e-05	8.67e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP2A6—lung cancer	1.76e-05	8.61e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GCLC—lung cancer	1.76e-05	8.61e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.76e-05	8.57e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AKR1C1—lung cancer	1.72e-05	8.39e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO1—lung cancer	1.67e-05	8.16e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—UGT1A1—lung cancer	1.67e-05	8.15e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.66e-05	8.13e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.64e-05	8.03e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNG11—lung cancer	1.61e-05	7.86e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALDOA—lung cancer	1.53e-05	7.48e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP2E1—lung cancer	1.5e-05	7.32e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NCOA3—lung cancer	1.49e-05	7.26e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NQO1—lung cancer	1.48e-05	7.24e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.45e-05	7.09e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ADCY1—lung cancer	1.45e-05	7.07e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCG2—lung cancer	1.45e-05	7.07e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.44e-05	7.02e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO2—lung cancer	1.42e-05	6.93e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HPGDS—lung cancer	1.42e-05	6.93e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.41e-05	6.89e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTT1—lung cancer	1.38e-05	6.72e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GCLC—lung cancer	1.36e-05	6.64e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP2A6—lung cancer	1.36e-05	6.64e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—STK11—lung cancer	1.34e-05	6.52e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO1—lung cancer	1.29e-05	6.3e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.25e-05	6.12e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTP1—lung cancer	1.24e-05	6.04e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CAT—lung cancer	1.2e-05	5.87e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.2e-05	5.84e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCB1—lung cancer	1.17e-05	5.71e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP2E1—lung cancer	1.16e-05	5.65e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TYMS—lung cancer	1.15e-05	5.61e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NQO1—lung cancer	1.14e-05	5.59e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTM1—lung cancer	1.14e-05	5.55e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP1A1—lung cancer	1.08e-05	5.26e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ERCC2—lung cancer	1.07e-05	5.21e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—STK11—lung cancer	1.03e-05	5.03e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTP1—lung cancer	9.54e-06	4.66e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CAT—lung cancer	9.28e-06	4.53e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—APOA1—lung cancer	9.24e-06	4.51e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCB1—lung cancer	9.03e-06	4.41e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TYMS—lung cancer	8.87e-06	4.33e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.85e-06	4.32e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTM1—lung cancer	8.77e-06	4.28e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CG—lung cancer	8.43e-06	4.12e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP1A1—lung cancer	8.31e-06	4.06e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ERCC2—lung cancer	8.24e-06	4.02e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—POMC—lung cancer	8.03e-06	3.92e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CREBBP—lung cancer	7.82e-06	3.82e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CD—lung cancer	7.41e-06	3.62e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALB—lung cancer	7.32e-06	3.57e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—APOA1—lung cancer	7.13e-06	3.48e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CG—lung cancer	6.51e-06	3.18e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CB—lung cancer	6.46e-06	3.16e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—lung cancer	6.4e-06	3.13e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—POMC—lung cancer	6.2e-06	3.03e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CREBBP—lung cancer	6.03e-06	2.95e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CD—lung cancer	5.72e-06	2.79e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALB—lung cancer	5.65e-06	2.76e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTEN—lung cancer	5.58e-06	2.73e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—EP300—lung cancer	5.33e-06	2.6e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CB—lung cancer	4.99e-06	2.44e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—lung cancer	4.94e-06	2.41e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTEN—lung cancer	4.31e-06	2.1e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—EP300—lung cancer	4.11e-06	2.01e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CA—lung cancer	3.94e-06	1.92e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AKT1—lung cancer	3.22e-06	1.57e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CA—lung cancer	3.04e-06	1.48e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AKT1—lung cancer	2.48e-06	1.21e-05	CbGpPWpGaD
